Table 1 Correlations between NORAD expression with clinical characteristics of ESCC patients
n (%) | P | |||
|---|---|---|---|---|
Total | High expression of NORAD | Low expression of NORAD | ||
Gender | ||||
Male | 53 | 31 (58.49%) | 22 (41.51%) | 0.129 |
Female | 40 | 17 (42.50%) | 23 (57.50%) | |
Age | ||||
< 60 | 71 | 39 (54.93%) | 32 (45.07%) | 0.255 |
≥ 60 | 22 | 9 (40.91%) | 13 (59.09%) | |
TNM stage | ||||
I + II | 63 | 24 (38.10%) | 39 (61.90%) | < 0.001 |
III | 30 | 24 (80.00%) | 6 (20.00%) | |
Invasion range | ||||
T1 + T2 | 62 | 27 (43.55%) | 35 (56.45%) | 0.021 |
T3 + T4 | 31 | 21 (67.74%) | 10 (32.26%) | |
Lymph node metastasis | ||||
Negative | 31 | 9 (29.03%) | 22 (70.97%) | 0.002 |
Positive | 62 | 39 (62.90%) | 23 (37.10%) | |
CDDP sensitivity | ||||
Sensitive | 82 | 38 (46.34%) | 44 (53.66%) | 0.005 |
Resistant | 11 | 10 (90.91%) | 1 (9.09%) | |